Publications by authors named "Natalya Gankina"

Background & Aims: Bepirovirsen, an antisense oligonucleotide, induces sustained reductions in hepatitis B surface antigen (HBsAg) and HBV DNA to below the lower limit of quantification (
Methods: In this phase IIb, multicentre, open-label trial, participants on stable nucleos(t)ide analogue (NA) therapy were randomised 1:1 to bepirovirsen 300 mg once weekly (plus loading dose on Days 4 and 11) for 24 (Arm 1) or 12 (Arm 2) weeks followed by Peg-IFN 180 μg once weekly for up to 24 weeks, with up to 36 weeks follow-up.

View Article and Find Full Text PDF
Article Synopsis
  • Limited hepatitis C virus (HCV) sequence data from Russian patients hampers understanding of how subtypes and resistance-associated substitutions (RAS) affect treatment outcomes.
  • Deep sequencing was conducted on HCV samples from 412 patients in Russia to analyze RAS and compare HCV strains with those found in other regions like Asia, Europe, and North America.
  • Results indicated that certain HCV genotypes, particularly GT1b and GT3a, have similar RAS profiles to those found in Europe and Asia, suggesting that understanding these relationships could improve treatment strategies in Russia.
View Article and Find Full Text PDF
Article Synopsis
  • Bictegravir combined with emtricitabine/tenofovir alafenamide (B/F/TAF) is an effective and well-tolerated HIV treatment, showing no resistance in treatment-naive and suppressed patients for 48 weeks.* -
  • In a phase 3 trial, 472 women with suppressed HIV were randomly assigned to either switch to B/F/TAF or continue their current regimen, with results demonstrating that switching was as effective as staying on the original treatment.* -
  • The study highlights B/F/TAF as a safe option for women living with HIV, providing essential insights into the efficacy and tolerability of antiretroviral therapy specifically for this group.*
View Article and Find Full Text PDF

Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is recommended prior to therapy. An effective pangenotypic therapy may potentially eliminate the need for genotyping.

View Article and Find Full Text PDF